Reports of an experimental drug that slowed advanced breast cancer in a clinical trial have stirred excitement at a national research meeting and breathed new life into a cancer-fighting strategy that had seemed to falter. In one study, the drug, palbociclib, doubled the length of time without disease progression in patients with metastatic estrogen receptor-positive breast cancer that had spread beyond the breast, compared with women who took only a hormonal treatment, researchers reported at the American Association for Cancer Research (AACR) in early April. Women in the study who received palbociclib also took the hormonal treatment, letrozole. Palbociclib is the …
The number of deaths from breast cancer has dropped over the past decade in the United States, but around the world, especially in less-developed countries, the number is rising. A report from the World Health Organization (WHO) in December 2013 said 522,000 women died from breast cancer in 2012 – a 14 percent increase compared with 2008.
Following radiation treatment or surgery to remove lymph nodes (lymphadenectomy), patients can develop lymphedema, a condition that involves abnormal swelling, usually in the arms or the legs, due to an accumulation of lymphatic fluids. This fluid buildup is caused by blockage or removal of lymph nodes or lymph vessels. Lymphedema is often associated with breast cancer patients, but can result from treatment of other cancers, such as melanoma, prostate, or advanced gynecological cancer. In addition to discomfort, lymphedema can also lead to infection, as the fluid buildup can increase bacteria growth. Pay attention to signs of infection, including pain, heat, …
Dana-Farber Cancer Institute’s Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH recently partnered with CancerConnect to answer questions about breast cancer therapies. Burstein and Mayer are breast oncologists in the Center for Breast Oncology at Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Q: What medications are helpful for depression after breast cancer treatment and while taking tamoxifen?
The 36th annual San Antonio Breast Cancer Symposium, which ran from Dec. 10-14, brought news of significant advances against a disease that strikes more than 230,000 women and 2,000 men in the United States each year. The more than 1,000 research papers presented by thousands of scientists and physicians ranged from laboratory explorations of the basic biology of the disease to studies that may change the treatment for patients with a variety of breast cancer subtypes. Here are summaries of the findings of several high-profile studies:
By Maggie Loucks, NP-C When I was diagnosed with breast cancer at age 28, during my last semester of graduate school, I remember thinking that this had to mean something. I needed to turn an unfortunate situation into something positive, so I decided to pursue oncology nursing where I felt I could make a difference.
One month after undergoing a mammogram live on “Good Morning America,” ABC reporter Amy Robach announced Monday she has been diagnosed with breast cancer and will undergo a double mastectomy later this week. At 40-years old, Robach is among a population of younger women with breast cancer. According to the American Cancer Society, about 5 percent of all breast cancer cases in the United States occur in women age 40 and younger.
Breast cancer is the most common cancer among American women, but only 5-10 percent of breast cancer cases are hereditary. Of those cases, roughly 20-25 percent are linked to mutations in the BRCA1 and BRCA2 genes (BRCA stands for BReast CAncer susceptibility). View the infographic below for more on the genetics of breast cancer.